

H g K g E cha ge, a d C ea g L ed a d The S c E cha ge f H g K g L ed a e e, b f he c e, f h, a ce e, a e e e e a a, ac, ac c e e e, a d e e, d, c a a ab ha, e e f a, h, e e a, g f e a ce, he h e a a f he c e, f h, a ce e.

**FOSUN PHARMA**

**复星医药**

上海復星醫藥（集團）股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

(a, c ed c a c a ed he Pe e', Re, b c f Ch a h ed ab )

(Stock Code: 02196)

## 2019 THIRD QUARTERLY REPORT

T f, i e e t f, i, f t R e 13.09(2) f, R e 13.10B t e R e G e t e L t, Se, t e T e S E f e H K L t e f, f, t e I f, I P, f, P f I A t e Se, t e f, R t e O f, e (C f. 571 t e L f, H K ).

T e / t e t f, t e e t 2019 S f, f F, P f, f a t f, (G ) C., D f,\* ( e “Company”, t e e / t t, f, e, e t e, t e “Group”) ( e “2019 Third Quarterly Report”). T e f, f e t t e e e f, e f, e / t t e PRC A, t t S f, f, B e E t e e f, f t e e f, e.

B, f, t e B f, f

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Chen Qiyu**

Cha a

S f, f, t e Pe e' Re, t C f, 29 O t e 2019

A, a he da e f h, a ce e, he e ea, e d ec, f he C a a e M. Che Q, M. Ya Fa g a d M. W, Yfa g; he -e ea, e d ec, f he C a a e M. X, Xa a g, M. Wa g Ca, M, M, Ha g a d M. La g Ja fe g; a d he de e de -e ea, e d ec, f he C a a e M. Ja g Xa, D. W g T Ya, Ke, M, L L g a d M. Ta g G, a g.

\* f de f ca, e,

## 1. IMPORTANT NOTICE

1.1 The \$% %et (the “Board”) \$% the the the the “Supervisory Committee”) the C \$ \$% %et , the \$% e \$ \$e et / \$ \$tt \$ the 2019 T %Q \$te Re t the G , %e t tt \$ \$ the \$ , e\$% ! the et the \$ \$ \$% e e \$ \$% tt \$ et \$ \$ e . tt , e , \$ , \$ \$% de e te et \$ %e e .

[illegible][illegible]

1.4 The 2019 T 1/2 Q 51 e 1 Re t t e G 1/2 e 5 1/2 e 1/2

## 2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

### 2.1 Major financial information

Unit: million RMB

	30 September 2019	31 December 2018	Ratio of change (%)
Total assets	78,569,297,725.65	70,551,361,387.48	11.36
Net assets attributable to equity holders of the parent	30,633,746,877.27	27,977,736,427.49	9.49
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Net income attributable to equity holders of the parent	2,328,355,784.17	2,087,826,458.74	11.52
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Operating revenue	21,227,618,679.11	18,142,384,871.95	17.01
Net profit attributable to equity holders of the parent	2,063,704,147.99	2,094,152,353.81	-1.45
Net profit attributable to equity holders of the parent (excluding non-recurring items)	1,722,388,028.34	1,591,668,096.39	8.21
Basic earnings per share (%)	7.21	8.00	Decrease 0.79 percentage points
Diluted earnings per share (RMB/share)	0.81	0.83	-2.41
Diluted earnings per share (RMB/share)	0.81	0.83	-2.41

Note: In the first nine months of 2019, the Group's total assets (in million RMB) increased by 11.36% compared with the same period of 2018. The increase was mainly due to the increase in the Group's operating revenue. The Group's net assets attributable to equity holders of the parent (in million RMB) increased by 9.49% compared with the same period of 2018. The increase was mainly due to the increase in the Group's net income attributable to equity holders of the parent. The Group's operating revenue (in million RMB) increased by 17.01% compared with the same period of 2018. The increase was mainly due to the increase in the Group's operating revenue. The Group's net profit attributable to equity holders of the parent (in million RMB) decreased by 1.45% compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent. The Group's net profit attributable to equity holders of the parent (excluding non-recurring items) (in million RMB) increased by 8.21% compared with the same period of 2018. The increase was mainly due to the increase in the Group's net profit attributable to equity holders of the parent.

The Group's basic earnings per share (in million RMB) decreased by 0.79 percentage points compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent. The Group's diluted earnings per share (in million RMB) decreased by 2.41% compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent. The Group's diluted earnings per share (in million RMB) decreased by 2.41% compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent.

The Group's operating revenue (in million RMB) increased by 17.01% compared with the same period of 2018. The increase was mainly due to the increase in the Group's operating revenue. The Group's net profit attributable to equity holders of the parent (in million RMB) decreased by 1.45% compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent.

The Group's net profit attributable to equity holders of the parent (in million RMB) decreased by 1.45% compared with the same period of 2018. The decrease was mainly due to the increase in the Group's net profit attributable to equity holders of the parent. The Group's net profit attributable to equity holders of the parent (excluding non-recurring items) (in million RMB) increased by 8.21% compared with the same period of 2018. The increase was mainly due to the increase in the Group's net profit attributable to equity holders of the parent.

Expenditure on the purchase of land and buildings

Unit: million GRC : RMB

Items	Jul – Sept 2019	Jan – Sept 2019
Grants received from the Government	6,698,974.15	54,877,229.54
Grants received from the Government (Note 1)	64,610,828.53	123,804,343.06
Provision of services to the Government	-95,402,673.43	231,996,093.58
Net result of the Government	48,756,541.22	27,391,712.25
Interest income (expense)	-15,445,568.08	-33,058,160.48
Exchange loss	-16,417,943.49	-63,695,098.30
Total	-7,199,841.10	341,316,119.65

2.2 The following table sets forth the percentage of the outstanding shares of common stock of the Company owned by the Top 10 shareholders of the Company as of the end of the period.

Unit: Shares

The shareholding status of the Top 10 shareholders				Name of shareholders		Shareholdingat the end ofth
Rank	Shareholder's name	Shareholding amount	Shareholding percentage	Shareholding amount		Shareholding percentage
				Shareholding amount	Shareholding percentage	



|--|--|

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOG (GROUP) COMPAN LIMITED*	938,095,290	RMB 100%	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,255,448	Ordinary shares	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB 100%	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	36,199,707	RMB 100%	36,199,707
NATIONAL SOCIAL SECURITY FUND 113 PORTFOLIO*	28,066,210	RMB 100%	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB 100%	25,824,892
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB 100%	24,067,700
NATIONAL SOCIAL SECURITY FUND 110 PORTFOLIO*	15,358,518	RMB 100%	15,358,518
ABU DHABI INVESTMENT AUTHORITY	13,790,532	RMB 100%	13,790,532
CHINA CONSTRUCTION BANK CORPORATION – CHINA-EUROPEALUE DISCOVERER EQUITY SECURITIES INVESTMENT FUND*	10,198,273	RMB 100%	10,198,273
Debt securities held by the Company		Convertible bonds	
Debt securities held by the Company		Convertible bonds	

Note 1: HKSCC NOMINEES LIMITED, the Hong Kong Securities Clearing Company Limited, is a wholly owned subsidiary of the Hong Kong Securities Clearing Company Limited, which is a subsidiary of the Hong Kong Securities Clearing Company Limited. The Company holds 34,993,500 shares of HKSCC NOMINEES LIMITED, representing 1.37% of the total shares of HKSCC NOMINEES LIMITED.

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED is a wholly owned subsidiary of the Hong Kong Securities Clearing Company Limited.

2.3 The Company has no other subsidiaries, branches, or associates. The Top 10 shareholders of the Company are as follows:

Notes:







(3) Statement of Cash Flow

Unit: million Yuan; Currency: RMB

Statement of Cash Flow				
Items	Jan – Sept 2019	Jan – Sept 2018	Ratio of change	Reasons of changes
Net increase/decrease in cash and cash equivalents	-2,560,243,375.55	-4,338,289,449.60	40.98%	Majorly due to the decrease in cash and cash equivalents of SHL, CMF and other subsidiaries, and the decrease in cash and cash equivalents of the Company.
Operating activities	47,762,255.60	-31,014,791.25	254.00%	Majorly due to the decrease in cash and cash equivalents of the Company.

3.2 Analysis of the change in cash and cash equivalents

1. The 2016-2018 cash flow statement of the Company shows that the cash and cash equivalents of the Company have decreased by 40.98% compared with the same period of 2018. The main reason for the decrease is the decrease in cash and cash equivalents of SHL, CMF and other subsidiaries, and the decrease in cash and cash equivalents of the Company. The decrease in cash and cash equivalents of SHL, CMF and other subsidiaries is mainly due to the decrease in cash and cash equivalents of SHL, CMF and other subsidiaries. The decrease in cash and cash equivalents of the Company is mainly due to the decrease in cash and cash equivalents of the Company.

The decrease in cash and cash equivalents of the Company is mainly due to the decrease in cash and cash equivalents of the Company. The decrease in cash and cash equivalents of the Company is mainly due to the decrease in cash and cash equivalents of the Company.

2. On September 19, 2019, the Company received the cash flow statement of the Company. The cash flow statement of the Company shows that the cash and cash equivalents of the Company have decreased by 40.98% compared with the same period of 2018. The main reason for the decrease is the decrease in cash and cash equivalents of SHL, CMF and other subsidiaries, and the decrease in cash and cash equivalents of the Company. The decrease in cash and cash equivalents of SHL, CMF and other subsidiaries is mainly due to the decrease in cash and cash equivalents of SHL, CMF and other subsidiaries. The decrease in cash and cash equivalents of the Company is mainly due to the decrease in cash and cash equivalents of the Company.



## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Unit: RMB Tens of thousands

Items	30 September 2019	31 December 2018
<b>Current assets:</b>		
Cash and cash equivalents	10,307,237,302.85	8,546,521,777.04
Financial assets at fair value through profit or loss	1,344,673,568.10	616,123,764.39
Derivatives	258,620,513.78	712,510,581.95
Trade receivables	4,463,034,533.86	3,623,640,740.82
Receivables from related parties	471,597,865.70	—
Prepaid expenses	596,927,301.93	472,144,580.30
Other receivables	577,591,869.92	447,434,579.55
Interest receivables	9,995,755.01	11,660,016.68
Dividends receivable	36,917,475.21	19,731,451.25
Inventory	3,858,842,830.18	3,287,392,199.46
Non-current receivables	—	—
Assets held for sale	1,162,820,637.56	—
Other current assets	368,970,686.90	295,958,970.62
Total current assets	23,410,317,110.78	18,001,727,194.13
<b>Non-current assets:</b>		
Deferred tax assets	117,956,750.00	67,562,000.00
Long-term equity investments	21,198,447,942.66	21,427,527,810.80
Other non-current assets	100,986,503.54	126,313,106.69
Other non-current receivables	2,100,733,208.89	2,505,806,955.75
Fixed assets	7,291,387,236.53	7,083,251,505.14
Intangible assets	2,942,095,697.03	2,039,800,319.91
Right-of-use assets	433,996,758.51	—
Investment properties	7,873,710,459.21	7,151,343,109.87
Deferred tax liabilities	2,676,735,574.42	2,040,773,501.88
Goodwill	9,187,137,617.57	8,853,913,413.52
Long-term liabilities	114,180,385.70	95,198,631.30
Deferred tax liabilities	242,021,035.79	173,134,814.17
Other non-current liabilities	879,591,445.02	985,009,024.32
Total non-current assets	55,158,980,614.87	52,549,634,193.35
Total assets	78,569,297,725.65	70,551,361,387.48

# Consolidated balance sheet (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
<b>Current liabilities:</b>		
Short-term borrowings	7,440,018,220.78	5,607,192,955.63
Accounts payable	266,942,486.20	149,003,072.96
Notes payable	2,233,670,981.77	2,184,280,272.14
Prepaid expenses	562,709,265.76	578,701,499.77
Other payables	451,969,450.66	478,905,270.26
Accounts receivable	4,178,903,272.34	3,237,217,890.12
Interest payable	220,768,148.00	187,344,429.18
Dividends payable	139,956,011.68	125,420,505.60
Contract liabilities	388,047,456.85	530,896,724.79
Financial liabilities at fair value through profit or loss	2,206,056,772.37	4,929,603,365.34
Other financial liabilities	1,599,149,293.47	227,445,337.32
Derivative financial liabilities	19,327,467,200.20	17,923,246,388.33
<b>Non-current liabilities:</b>		
Long-term borrowings	8,816,140,333.28	8,630,661,547.43
Borrowings due within one year	5,781,204,728.90	4,039,456,986.21
Lease liabilities	307,212,833.42	—
Long-term payables	252,679,111.96	416,889,805.19
Deferred income	358,341,043.66	363,489,177.57
Deferred income tax liabilities	2,895,818,060.31	2,908,359,008.27
Other non-current liabilities	2,878,227,018.69	2,676,545,098.82
Derivative non-current liabilities	21,289,623,130.22	19,035,401,623.49
Other non-current liabilities	40,617,090,330.42	36,958,648,011.82
<b>Equity:</b>		
Preferred shares (non-cumulative)	2,562,898,545.00	2,563,060,895.00
Capital reserves	11,918,086,638.94	10,544,648,359.54
Less: Treasury shares	—	1,711,169.00
Other equity components	-238,833,703.62	-274,779,732.99
Subtotal	2,373,685,050.45	2,374,999,312.51
Unrealized gains	14,017,910,346.50	12,771,518,762.43
Derivative financial assets (non-cumulative) at fair value through profit or loss	30,633,746,877.27	27,977,736,427.49
Non-current interest receivable	7,318,460,517.96	5,614,976,948.17
Derivative financial assets (non-cumulative)	37,952,207,395.23	33,592,713,375.66
Derivative financial assets (non-cumulative) at fair value through profit or loss	78,569,297,725.65	70,551,361,387.48

Legal Representative:  
Chen Qiyu

Chief Financial Officer:  
Guan Xiaohui

Deputy Chief Accounting Officer:  
Chen Zhanyu

# Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Unit: 100,000 RMB Yuan

Items	30 September 2019	31 December 2018
<b>Current assets:</b>		
Cash and cash equivalents	1,106,498,344.52	850,102,168.54
Financial assets		
Prepaid expenses		
Other receivables	6,407,634,690.21	6,914,735,852.92
Interest receivables	299,410,098.84	230,691,574.83
Dividend receivables	354,609,680.05	307,409,680.05
Intangible assets	—	—
Non-current receivables	2,536,000,000.00	1,625,000,000.00
Other receivables	239,000,000.00	158,570,000.00
Total current assets	10,289,133,034.73	9,548,408,021.46
<b>Non-current assets:</b>		
Deferred tax assets	6,011,804,080.60	5,465,151,645.71
Long-term equity investments	23,961,991,164.92	22,999,277,541.00
Other long-term investments	37,689,534.30	37,626,487.24
Other non-current assets	147,179,403.98	184,188,803.45
Fixed assets	6,217,807.54	7,158,298.77
Construction in progress	2,305,418.41	2,305,418.41
Intangible assets	1,398,139.68	1,840,272.04
Deferred tax liabilities		
Goodwill		
Long-term liabilities		
Deferred tax liabilities		
Total non-current assets	30,168,585,549.43	28,697,548,466.62
Total assets	40,457,718,584.16	38,245,956,488.08

# Balance Sheet of the Parent Company (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
<b>Current liabilities:</b>		
Short-term borrowings	3,825,000,000.00	2,959,000,000.00
Accounts payable		
Prepaid expenses		
Contract liabilities		
Other current liabilities	94,480,035.63	124,637,901.93
Total current liabilities	25,239,506.72	43,694,651.68
Other non-current liabilities	1,715,449,403.09	1,357,247,173.94
Long-term borrowings	213,542,735.45	172,658,261.16
Long-term debt	229,468.00	229,468.00
Long-term equity investments	1,267,088,795.71	3,769,010,861.94
Other non-current liabilities	1,304,675,980.01	5,313,103.87
Total non-current liabilities	8,231,933,721.16	8,258,903,693.36
<b>Non-current liabilities:</b>		
Long-term borrowings	346,740,000.00	66,740,000.00
Long-term debt	5,781,204,728.90	4,039,456,986.21
Long-term equity investments		
Deferred income	325,000.00	550,000.00
Deferred income	1,151,018,873.79	1,151,018,873.79
Other non-current liabilities		
Total non-current liabilities	7,279,288,602.69	5,257,765,860.00
Total non-current liabilities	15,511,222,323.85	13,516,669,553.36
<b>Equity:</b>		
Capital	2,562,898,545.00	2,563,060,895.00
Reserves	14,247,927,508.28	14,231,054,756.04
Other equity	—	1,711,169.00
Other equity	-327,370,661.53	-279,100,142.24
Other equity	1,247,565,522.50	1,247,565,522.50
Other equity	7,215,475,346.06	6,968,417,072.42
Total equity	24,946,496,260.31	24,729,286,934.72
Total equity	40,457,718,584.16	38,245,956,488.08

Legal Representative:  
Chen Qiyu

Chief Financial Officer:  
Guan Xiaohui

Director of Accounting Department:  
Chen Zhanyu

*Journal of the American Statistical Association* – September 2019

Unit: 15      Grade: RMB      Date:      %:      %:      %:

[illegible]

# Consolidated Income Statement (Continued)

January – September 2019

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating income, after tax	-9,016,755.16	-122,010,941.32	34,958,479.93	-532,197,468.31
Operating income before tax				
Income tax expense	7,142,372.12	-173,180,224.69	35,946,029.37	-571,964,925.72
( ) Operating income	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
1. Contribution margin	—	—	—	—
2. Selling expenses	—	—	—	—
3. Cost of sales	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
4. Cost of sales	—	—	—	—
( ) Operating income	6,998,219.31	-176,937,040.20	62,640,198.48	-470,443,011.66
1. Selling expenses	-27,514,726.87	22,492,035.64	-57,540,529.80	29,149,580.97
2. Depreciation	34,512,946.18	-199,429,075.84	120,180,728.28	-499,592,592.63
Operating income before tax	-16,159,127.28	51,169,283.37	-987,549.44	39,767,457.41
II. Total operating income	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Total operating income before tax	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Total operating income	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings				
( ) Basic earnings	0.22	0.20	0.81	0.83
( ) Diluted earnings	0.22	0.20	0.81	0.83

Legal Representative:  
Chen Qiyu

Chief Financial Officer:  
Guan Xiaohui

Deputy Accounting Director:  
Chen Zhanyu



# Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Unit: RMB Tens of thousands

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating income	3,815,974.06	—	5,685,313.69	9,433.96
Less: Operating expenses	—	—	—	—
Transportation expenses	1,138,885.77	—	2,411,699.94	43,754.06
Selling expenses	—	—	—	—
General and administrative expenses	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
Research and development expenses	1,400,270.20	—	2,952,245.60	—
Finance expenses	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
Interest income	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
Interest expense	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
Addition of assets	—	—	—	—
Disposal of assets	—	—	—	—
Profit before tax	110,486.49	75,000.00	300,849.09	225,000.00
Income tax expense (“—” for credit)	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
Income before tax	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
Goodwill impairment expense (“—” for credit)	—	—	—	—
Goodwill impairment expense (“—” for credit)	-14,794,694.59	66,221,631.43	-36,067,868.78	90,531,856.25
Goodwill impairment expense (“—” for credit)	7,349.80	-886.58	7,349.80	-886.58
II. Operating loss (“—” for credit)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Profit before tax	—	—	—	—
Less: Non-operating income	—	—	—	—
III. Total loss (“—” for credit)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Less: Income tax expense	—	—	—	—
IV. Net loss (“—” for credit)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) Net loss (“—” for credit)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) Net loss (“—” for credit)	—	—	—	—











#### 4.2 Information on adjustments to the initial implementation of financial statements at the beginning of the year for the initial implementation of New Financial Instruments Standards, New Income Standards and New Lease Standards

## Consolidated balance sheet

Unit: 1.5 Grade: 7 : RMB

[illegible]

Items	31 December 2018	1 January 2019	Adjustment
<b>Non-current liabilities:</b>			
Long-term debt	8,630,661,547.43	8,630,661,547.43	
Borrowings	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provisions	—	—	
Lease liabilities	—	325,992,167.00	-325,992,167.00
Long-term debt	416,889,805.19	398,095,841.52	18,793,963.67
Debt	363,489,177.57	363,489,177.57	
Debt	2,908,359,008.27	2,908,359,008.27	
Other	2,676,545,098.82	2,676,545,098.82	
Total	19,035,401,623.49	19,342,599,826.82	-307,198,203.33
Total	36,958,648,011.82	37,348,299,890.45	-389,651,878.63
<b>Equity (or shareholders' interests):</b>			
Preferred shares	2,563,060,895.00	2,563,060,895.00	
Common shares	10,544,648,359.54	10,544,648,359.54	
Lease liabilities	1,711,169.00	1,711,169.00	
Other	-274,779,732.99	-274,779,732.99	
Shareholders' equity	2,374,999,312.51	2,374,999,312.51	
Unrealized gains	12,771,518,762.43	12,771,518,762.43	
Total	27,977,736,427.49	27,977,736,427.49	
Net	5,614,976,948.17	5,614,976,948.17	
Total	33,592,713,375.66	33,592,713,375.66	
Total	70,551,361,387.48	70,941,013,266.11	-389,651,878.63

Expenditure on capital:

For 1 January 2019, the Group's net lease liability is \$5,551,361,387.48, which is the same as the MOF.

In the year ended 31 December 2019, the Group's net lease liability is \$5,551,361,387.48, which is the same as the MOF. The Group's net lease liability is \$5,551,361,387.48, which is the same as the MOF.



## Balance Sheet of the Parent Company

Unit: 100,000 Yuan      Currency: RMB

Items	31 December 2018	1 January 2019	Adjustment
<b>Current assets:</b>			
Cash and cash equivalents	850,102,168.54	850,102,168.54	
Accounts receivable	6,914,735,852.92	6,914,735,852.92	
Interest receivable	230,691,574.83	230,691,574.83	
Dividends receivable	307,409,680.05	307,409,680.05	
Financial assets measured at fair value	1,625,000,000.00	1,625,000,000.00	
Other financial assets	158,570,000.00	158,570,000.00	
Total current assets	9,548,408,021.46	9,548,408,021.46	
<b>Non-current assets:</b>			
Long-term equity investments	5,465,151,645.71	5,465,151,645.71	
Long-term debt investments	22,999,277,541.00	22,999,277,541.00	
Other long-term investments	37,626,487.24	37,626,487.24	
Intangible assets	184,188,803.45	184,188,803.45	
Goodwill	7,158,298.77	7,158,298.77	
Deferred income tax assets	2,305,418.41	2,305,418.41	
Other non-current assets	1,840,272.04	1,840,272.04	
Total non-current assets	28,697,548,466.62	28,697,548,466.62	
Total assets	38,245,956,488.08	38,245,956,488.08	
<b>Current liabilities:</b>			
Short-term debt	2,959,000,000.00	2,959,000,000.00	
Accounts payable	124,637,901.93	124,637,901.93	
Prepaid expenses	43,694,651.68	43,694,651.68	
Other payables	1,357,247,173.94	1,357,247,173.94	
Interest payable	172,658,261.16	172,658,261.16	
Dividends payable	229,468.00	229,468.00	
Financial liabilities measured at fair value	3,769,010,861.94	3,769,010,861.94	
Other financial liabilities	5,313,103.87	5,313,103.87	
Total current liabilities	8,258,903,693.36	8,258,903,693.36	

